# Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients

> **NCT01415011** · PHASE2 · COMPLETED · sponsor: **University College, London** · enrollment: 39 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Afatinib (BIBW 2992)

## Key facts

- **NCT ID:** NCT01415011
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2015-08
- **Final completion:** 2018-11-30
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2019-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01415011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01415011, "Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01415011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*